Skip to main content
Top
Published in: Lung 6/2020

01-12-2020 | Lung Cancer | LUNG CANCER

A Multidisciplinary Lung Cancer Program: Does It Reduce Delay Between Diagnosis and Treatment?

Authors: Denise Albano, Thomas Bilfinger, Melissa Feraca, Stephen Kuperberg, Barbara Nemesure

Published in: Lung | Issue 6/2020

Login to get access

Abstract

Introduction

Lung cancer is the leading cause of cancer death in the USA, claiming more than 140,000 deaths annually. Delays in diagnosis and treatment can lead to missed opportunities for both curative and life prolonging therapies. This study aimed to evaluate duration of time to diagnosis and first treatment, as well as investigate reasons for delays in care.

Methods

This retrospective study included all lung cancer cases diagnosed by Stony Brook’s Lung Cancer Evaluation Center (LCEC) between 2013 and 2019. Demographic, radiologic, pathologic and clinical variables were investigated, including cancer staging, histology, and medical and family histories. Evaluations included the determination of median time from initial encounter to diagnosis, median time from diagnosis to start of treatment and an exploration of the factors that influence possible causes for delays in care.

Results

The LCEC’s comprehensive multidisciplinary lung nodule program yielded a median length of time from CT to PET of 11 days, PET to procedure of 13 days, procedure to treatment consult of 9 days, and from consult to treatment of 9 days. LCEC patients experienced an overall median of 44 days from initial presentation to first treatment compared to the national ideal of 62 days, thereby representing a 29% reduction in time from first CT to onset of treatment.

Conclusion

Delays in lung cancer diagnosis and treatment can negatively impact patient morbidity and mortality. This study suggests that a coordinated multidisciplinary lung cancer program may reduce delays in care, thereby improving patient outcomes.
Literature
1.
go back to reference Jones GS, Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med 18:s41–s46CrossRef Jones GS, Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med 18:s41–s46CrossRef
2.
go back to reference Ellis PM (2012) The importance of multidisciplinary team management of patients with non-small-cell lung cancer. Curr Onc 19:S7–S15 Ellis PM (2012) The importance of multidisciplinary team management of patients with non-small-cell lung cancer. Curr Onc 19:S7–S15
3.
go back to reference Bilfinger TV et al (2018) Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach. Clin Lung Canc 19(4):346–351CrossRef Bilfinger TV et al (2018) Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach. Clin Lung Canc 19(4):346–351CrossRef
5.
go back to reference Mackillop WJ (2007) Killing time: the consequences of delays in radiotherapy. Radiother Oncol 84(1):1–4PubMedCrossRef Mackillop WJ (2007) Killing time: the consequences of delays in radiotherapy. Radiother Oncol 84(1):1–4PubMedCrossRef
6.
go back to reference The Lung Clinical Expert Group (2017) National Optimal Clinical Pathway for suspected and confirmed lung cancer:Referral to treatment. The Lung Clinical Expert Group (2017) National Optimal Clinical Pathway for suspected and confirmed lung cancer:Referral to treatment.
7.
go back to reference Koyi H, Hillerdal G, Branden E (2002) Patient’s and doctors’ delays in the diagnosis of chest tumors. Lung Canc 35(1):53–57CrossRef Koyi H, Hillerdal G, Branden E (2002) Patient’s and doctors’ delays in the diagnosis of chest tumors. Lung Canc 35(1):53–57CrossRef
8.
10.
go back to reference Hamann HA et al (2014) Stigma among patients with lung cancer: a patient-reported measurement model. Psycho-oncol 23(1):81–92CrossRef Hamann HA et al (2014) Stigma among patients with lung cancer: a patient-reported measurement model. Psycho-oncol 23(1):81–92CrossRef
12.
14.
go back to reference Salomaa ER et al (2005) Delays in the diagnosis and treatment of lung cancer. Chest 128(4):2282–2288PubMedCrossRef Salomaa ER et al (2005) Delays in the diagnosis and treatment of lung cancer. Chest 128(4):2282–2288PubMedCrossRef
15.
go back to reference Stinchcombe TE et al (2007) Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer. J Thorac Oncol 2(9):819–826PubMedCrossRef Stinchcombe TE et al (2007) Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer. J Thorac Oncol 2(9):819–826PubMedCrossRef
16.
go back to reference Leiro-Fernández V et al (2019) Predicting delays in lung cancer diagnosis and staging. Thorac Canc 10(2):296–303CrossRef Leiro-Fernández V et al (2019) Predicting delays in lung cancer diagnosis and staging. Thorac Canc 10(2):296–303CrossRef
17.
go back to reference Vidaver RM et al (2016a) Typical Time to Treatment of Patients With Lung Cancer in a Multisite US-based study. J Oncol Pract 12(6):e643–e653PubMedCrossRef Vidaver RM et al (2016a) Typical Time to Treatment of Patients With Lung Cancer in a Multisite US-based study. J Oncol Pract 12(6):e643–e653PubMedCrossRef
18.
22.
go back to reference Olsson JK, Schultz EM, Gould MK (2009) Timeliness of care in patients with lung cancer: a systematic review. Thorax 64(9):749–756PubMedCrossRef Olsson JK, Schultz EM, Gould MK (2009) Timeliness of care in patients with lung cancer: a systematic review. Thorax 64(9):749–756PubMedCrossRef
23.
go back to reference Vidaver RM et al (2016b) Typical Time to Treatment of Patients With Lung Cancer in a Multisite US-based study. J Oncol Prac 12(6):e643–e653CrossRef Vidaver RM et al (2016b) Typical Time to Treatment of Patients With Lung Cancer in a Multisite US-based study. J Oncol Prac 12(6):e643–e653CrossRef
24.
go back to reference Denton E, Conron M (2016) Improving outcomes in lung cancer: the value of the multidisciplinary health care team. J Multidisciplin Healthcare 9:137–144 Denton E, Conron M (2016) Improving outcomes in lung cancer: the value of the multidisciplinary health care team. J Multidisciplin Healthcare 9:137–144
27.
go back to reference Gaga M et al (2013) An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med 188(4):503–507PubMedPubMedCentralCrossRef Gaga M et al (2013) An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med 188(4):503–507PubMedPubMedCentralCrossRef
28.
go back to reference Wright FC et al (2007) Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 43(6):1002–1010PubMedCrossRef Wright FC et al (2007) Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 43(6):1002–1010PubMedCrossRef
34.
go back to reference Carlson LE et al (2004) High levels of untreated distress and fatigue in cancer patients. Br J Canc 90(12):2297–2304CrossRef Carlson LE et al (2004) High levels of untreated distress and fatigue in cancer patients. Br J Canc 90(12):2297–2304CrossRef
35.
go back to reference Vinod SK (2015) Decision making in lung cancer—how applicable are the guidelines? Clin Oncol 27(2):125–131CrossRef Vinod SK (2015) Decision making in lung cancer—how applicable are the guidelines? Clin Oncol 27(2):125–131CrossRef
Metadata
Title
A Multidisciplinary Lung Cancer Program: Does It Reduce Delay Between Diagnosis and Treatment?
Authors
Denise Albano
Thomas Bilfinger
Melissa Feraca
Stephen Kuperberg
Barbara Nemesure
Publication date
01-12-2020
Publisher
Springer US
Published in
Lung / Issue 6/2020
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-020-00404-8

Other articles of this Issue 6/2020

Lung 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.